var data={"title":"Ranibizumab: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ranibizumab: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/229014?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ranibizumab-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ranibizumab: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025066\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lucentis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5376866\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lucentis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025070\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Angiogenesis Inhibitor;</li>\n      <li>\n        Monoclonal Antibody;</li>\n      <li>\n        Ophthalmic Agent;</li>\n      <li>\n        Vascular Endothelial Growth Factor (VEGF) Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025114\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Age-related macular degeneration (AMD), neovascular (wet):</b> Intravitreal: 0.5 mg once a month (approximately every 28 days). Frequency may be reduced (eg, 4 to 5 injections over 9 months) after the first 3 injections or may be reduced after the first 4 injections to once every 3 months if monthly injections are not feasible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> A regimen averaging 4 to 5 doses over 9 months is expected to maintain visual acuity and an every-3-month dosing regimen has reportedly resulted in a ~5 letter (1 line) loss of visual acuity over 9 months, as compared to monthly dosing which may result in an additional ~1 to 2 letter gain.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic macular edema (DME):</b> Intravitreal: 0.3 mg once a month (approximately every 28 days); in clinical trials, monthly doses of 0.5 mg were also studied (Massin 2010; Mitchell 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic retinopathy (DR):</b> Intravitreal: 0.3 mg once a month (approximately every 28 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Macular edema following retinal vein occlusion (RVO):</b> Intravitreal: 0.5 mg once a month  (approximately every 28 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myopic choroidal neovascularization (mCNV): </b>Intravitreal: 0.5 mg once a month (approximately every 28 days) for up to 3 months; may retreat if necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025115\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025116\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025117\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. However, significant systemic exposure is not expected.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025123\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravitreal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lucentis: 0.3 mg/0.05 mL (0.05 mL); 0.5 mg/0.05 mL (0.05 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravitreal [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lucentis: 0.5 mg/0.05 mL (0.05 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025068\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5950141\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Intravitreal [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Lucentis: 10 mg/mL (0.23 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025118\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">For ophthalmic intravitreal injection only. Each vial or prefilled syringe should only be used for the treatment of a single eye. If the contralateral eye requires treatment, a new vial or prefilled syringe should be used and the sterile field, syringe, gloves, drapes, eyelid speculum, filter, and injection needles should be changed before ranibizumab is administered to the other eye. Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure. Refer to manufacturer labeling for additional detailed information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3030717\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic macular edema:</b> Treatment of diabetic macular edema (DME).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic retinopathy:</b> Treatment of diabetic retinopathy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Macular degeneration:</b> Treatment of neovascular (wet) age-related macular degeneration (AMD)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Macular edema:</b> Treatment of macular edema following retinal vein occlusion (RVO)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Myopic choroidal neovascularization:</b> Treatment of myopic choroidal neovascularization (mCNV).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15241855\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ranibizumab may be confused with bevacizumab, ramucirumab</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025079\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>As reported with AMD, RVO, and DME studies: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Arterial thromboembolism (AMD trials during first year: 2%; DME trials at 3 years: 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Foreign body sensation of eye (7% to 16%), headache (6% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (4% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (2% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctival hemorrhage (47% to 74%), eye pain (17% to 35%), vitreous opacity (7% to 27%), increased intraocular pressure (7% to 24%), blurred vision (5% to 18%), intraocular inflammation (1% to 18%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Cataract, blepharitis, dry eye syndrome, eye irritation, increased lacrimation, maculopathy, ocular hyperemia, eye pruritus, and vitreous detachment occurred in &gt;10% of patients, but also occurred either in similar percentages to the control or more often in the control in some studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (5% to 16%), bronchitis (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Peripheral edema (6%), atrial fibrillation (1% to 5%), cerebrovascular accident (AMD trials during 2 years: 3%; DME trials at 3 years: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral neuropathy (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypercholesterolemia (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (9% to 10%), constipation (8%), gastroesophageal reflux disease (1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Chronic renal failure (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody formation (1% to 9%), seasonal allergy (8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Retinal degeneration (1% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Conjunctival hyperemia, eye discomfort, posterior capsule opacification, and retinopathy occurred in 1% to 10% of patients, but also occurred in similar percentages to the control or more often in the control in some of the studies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (9%), cough (5% to 9%), sinusitis (3% to 8%), chronic obstructive pulmonary disease (3% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Wound healing impairment (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>All indications:</b> &lt;1%, postmarketing, and/or case reports: Anterior chamber inflammation, anxiety, back pain, corneal edema, corneal erosion, coronary artery occlusion, decreased visual acuity, dizziness, endophthalmitis, epithelial keratopathy, eye discharge (lid margin), eyelid pain, hypoglycemia, iatrogenic traumatic cataracts, intestinal obstruction, photophobia, retinal pigment epithelium tear, rhegmatogenous retinal detachment, rhinorrhea, urticaria</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>As reported with choroidal neovascularization secondary to pathologic myopia (not in US labeling):</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctival hemorrhage (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (8%), migraine (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Diabetes mellitus (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (3%), nausea (2%), toothache (2%), vomiting (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (3%), bacteriuria (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Bleeding at injection site (4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (2%), herniated disk (2%), limb pain (2%), osteoporosis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Punctate keratitis (8%), vitreous opacity (5%), dry eye syndrome (4%), eye pain (4%), increased intraocular pressure (3%), blepharitis (2%), conjunctivitis (2%), eyelid edema (2%), retinal hole without detachment (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (3%), pharyngitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%: Allergic conjunctivitis, arthralgia, bronchitis, cataract, conjunctival edema, corneal erosion, cough, eye irritation, hepatic insufficiency, hypercholesterolemia, hypersensitivity, increased intracranial pressure, iridocyclitis, ocular hyperemia, pain at injection site, retinal hemorrhage, sciatica, tendonitis, uveitis, viral conjunctivitis (adenovirus), vitreous detachment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025075\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to ranibizumab or any component of the formulation; ocular or periocular infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Active intraocular inflammation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025076\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endophthalmitis/retinal detachment: Intravitreous injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques should be used. Patients should be monitored for potential infection and report any signs of infection (eg, eye pain or redness, photophobia, blurred vision) immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity may present as severe intraocular inflammation; instruct patients to report intraocular inflammation that increases with severity. Rare hypersensitivity reactions (including anaphylaxis) have been associated with another VEGF inhibitor, pegaptanib, occurring within several hours of use; monitor closely. Equipment and appropriate personnel should be available for monitoring and treatment of anaphylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Increased intraocular pressure: Prior to and following intravitreal injection, intraocular pressure may increase. Onset is seen within 60 minutes postinjection. Monitor intraocular pressure before and after injection and manage accordingly.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thromboembolic events: Risk of thromboembolic events, particularly stroke, may be increased following intravitreal administration of VEGF inhibitors. Use caution in patients with known risk factors (eg, history of stroke, TIA).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetic macular edema (DME) and diabetic retinopathy (DR): Pooled analysis of trials involving DME and DR patients revealed a higher incidence of fatal events in patients treated with ranibizumab compared to control (3% in patients treated with 0.3 mg in the first 2 years compared to 1% in the control). Overall, the incidence of fatalities was consistent with deaths normally observed in patients with advanced diabetic complications; however, a potential association between fatal events and intravitreal administration of VEGF inhibitors cannot be excluded.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299982\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2J2 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222715\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10337&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025072\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Based on its mechanism of action, adverse effects on pregnancy would be expected. Information related to use in pregnancy is limited (Jouve 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20548220\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if ranibizumab is present in breast milk. The manufacturer recommends that caution be exercised when administering ranibizumab to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025120\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Intraocular pressure (prior to and  30 minutes following injection via tonometry); consider checking for perfusion of the optic nerve head immediately following injection; signs of infection/inflammation (for first week following injection); retinal perfusion, endophthalmitis; visual acuity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025108\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Ranibizumab is a recombinant humanized monoclonal antibody fragment which binds to and inhibits human vascular endothelial growth factor A (VEGF-A). Ranibizumab inhibits VEGF from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3025110\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Low levels are detected in the serum following intravitreal injection </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Vitreous: ~9 days</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322947\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Lucentis Intravitreal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.3 mg/0.05 mL (0.05 mL): $1,404.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/0.05 mL (0.05 mL): $2,340.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Lucentis Intravitreal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/0.05 mL (0.05 mL): $2,340.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5378700\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Accentrix (MY);</li>\n      <li>Lucentis (AE, AR, AT, AU, BE, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GR, HK, HR, HU, ID, IE, IL, IN, IT, JO, JP, KR, KW, LB, LK, LT, LU, MT, MY, NO, NZ, PE, PH, PL, PT, QA, RO, RU, SA, SE, SG, SI, SK, TH, TR, TW, UA, ZA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Gaudreault J, Fei D, Rusit J, et al, &ldquo;Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) After a Single Intravitreal Administration,&rdquo; <i>Invest Ophthalmol Vis Sci</i>, 2005, 46(2):726-33.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranibizumab-drug-information/abstract-text/15671306/pubmed\" target=\"_blank\" id=\"15671306\">15671306</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heier JS, Antoszyk AN, Pavan PR, et al, &ldquo;Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration: A Phase I/II Multicenter, Controlled, Multidose Study,&rdquo; <i>Ophthalmology</i>, 2006, 113(4):633-42.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jouve L, Akesbi J, Nordmann JP. Safety and efficacy of ranibizumab for pregnant women in idiopathic choroidal neovascularization. <i>Acta Ophthalmol</i>. 2015;93(7):597-598.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranibizumab-drug-information/abstract-text/25483229/pubmed\" target=\"_blank\" id=\"25483229\">25483229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucentis (ranibizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucentis (ranibizumab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada, Inc; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massin P, Bandello F, Garweg JG, et al, &ldquo;Safety and Efficacy of Ranibizumab in Diabetic Macular Edema (RESOLVE Study): A 12-Month, Randomized, Controlled, Double-Masked, Multicenter Phase II Study,&rdquo; <i>Diabetes Care</i>, 2010, 33(11):2399-405.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranibizumab-drug-information/abstract-text/20980427/pubmed\" target=\"_blank\" id=\"20980427\">20980427</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mitchell P, Bandello F, Schmidt-Erfurth U, et al, &ldquo;The RESTORE STUDY: Ranibizumab Monotherapy or Combined With Laser versus Laser Monotherapy for Diabetic Macular Edema,&rdquo; <i>Ophthalmology</i>, 2011, 118(4):615-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranibizumab-drug-information/abstract-text/21459215/pubmed\" target=\"_blank\" id=\"21459215\">21459215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld PJ, Brown DM, Heier JS, et al, &ldquo;Ranibizumab for Neovascular Age-Related Macular Degeneration,&rdquo; <i>N Engl J Med</i>, 2006, 355(14):1419-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranibizumab-drug-information/abstract-text/17021318/pubmed\" target=\"_blank\" id=\"17021318\">17021318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rosenfeld PJ, Rich RM and Lalwani, &ldquo;Ranibizumab: Phase III Clinical Trial Results,&rdquo; <i>Ophthalmol Clin North Am</i>, 2006, 19(3):361-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranibizumab-drug-information/abstract-text/16935211/pubmed\" target=\"_blank\" id=\"16935211\">16935211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolf S, Balciuniene VJ, Laganovska G, et al. RADIANCE: A randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. <i>Ophthalmology</i>. 2014;121(3):682-692.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ranibizumab-drug-information/abstract-text/24326106/pubmed\" target=\"_blank\" id=\"24326106\">24326106</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10337 Version 106.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F3025066\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5376866\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F3025070\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F3025114\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F3025115\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F3025116\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F3025117\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F3025123\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F3025068\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F5950141\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F3025118\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F3030717\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F15241855\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F3025079\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F3025075\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F3025076\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299982\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222715\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3025072\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20548220\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3025120\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F3025108\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F3025110\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322947\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5378700\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10337|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ranibizumab-patient-drug-information\" class=\"drug drug_patient\">Ranibizumab: Patient drug information</a></li></ul></div></div>","javascript":null}